Topic:
Infectious Diseases
Latest Headlines
Latest Headlines
Nasal HIV vax safe, triggers immune response
The therapeutic HIV vaccine that the company nearly shelved in October 2011, Bionor's Vacc-4X, was safe given nasally to HIV-positive patients also on antiretrovirals.
MMR and autism: Italy's courts get involved
An Italian health news website seems to have reported that an Italian court has ruled that an MMR vaccine caused autism in a child.
Study: Further insight into Merck HIV vax infection increase
A recent study published in the Journal of Infectious Disease confirmed that a vaccine study halted in 2007 showed an increased risk of infection in the first 18 months for subgroups of the men who were vaccinated, but that this difference disappeared after 18 months.
Pneumococcal vax cuts deaths, but cases tripled
While vaccines against Streptococcus pneumoniae have cut the number of deaths from this bug that can cause pneumonia and meningitis, the number of cases has tripled in the past 50 years.
Japan OKs Sanofi's inactivated polio vaccine
Japan has granted marketing approval for its first inactivated polio vaccine (IPV), Sanofi's Imovax Polio, and will begin using the vaccine in public immunization programs beginning Sept. 1.
GSK's Nimenrix gets green light in Europe
GlaxoSmithKline's meningitis vaccine Nimenrix has been granted approval in Europe by the Committee for Medicinal Products for Human Use (CHMP).
Celebrating vaccines: World Immunization Week 2012
The World Health Organization has declared this week to be World Immunization Week.
Nigeria commits to AIDS vaccine development
In Nigeria, around 3.3 million people were living with HIV/AIDS in 2010. To try to combat this, the country is kick-starting its vaccine program again.
'Hypervirulent' salmonella could overwhelm a vaccine
Researchers in the U.S. and Australia have found that salmonella bacteria have the capacity to overwhelm vaccines.
Taiwan's RSV vaccine heads toward the clinic
Taiwanese researchers are developing a virus-based RSV vaccine that could complete preclinical studies next year, and has already shown signs of efficacy.
